IN2012DN02200A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02200A
IN2012DN02200A IN2200DEN2012A IN2012DN02200A IN 2012DN02200 A IN2012DN02200 A IN 2012DN02200A IN 2200DEN2012 A IN2200DEN2012 A IN 2200DEN2012A IN 2012DN02200 A IN2012DN02200 A IN 2012DN02200A
Authority
IN
India
Prior art keywords
vivo
gcmaf
macrophages
nagalase
contacting
Prior art date
Application number
Other languages
English (en)
Inventor
Charles Knezevich
Robert Silvetz
Original Assignee
Charles Knezevich
Robert Silvetz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles Knezevich, Robert Silvetz filed Critical Charles Knezevich
Publication of IN2012DN02200A publication Critical patent/IN2012DN02200A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687Chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2200DEN2012 2009-08-22 2010-08-23 IN2012DN02200A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23608809P 2009-08-22 2009-08-22
PCT/US2010/046356 WO2011028485A2 (en) 2009-08-22 2010-08-23 Tumoricidal, bactericidal, or viricidal macrophage activation

Publications (1)

Publication Number Publication Date
IN2012DN02200A true IN2012DN02200A (enExample) 2015-08-21

Family

ID=43649882

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2200DEN2012 IN2012DN02200A (enExample) 2009-08-22 2010-08-23

Country Status (8)

Country Link
US (1) US20110123591A1 (enExample)
EP (1) EP2467154A4 (enExample)
CN (1) CN102596223A (enExample)
AU (1) AU2010289901A1 (enExample)
CA (1) CA2771900A1 (enExample)
IN (1) IN2012DN02200A (enExample)
TW (1) TW201113372A (enExample)
WO (1) WO2011028485A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694088B1 (en) * 2011-04-07 2017-06-07 Efranat Ltd. Macrophage activating factor for pharmaceutical compositions
EP3563864A1 (en) * 2013-01-18 2019-11-06 Kline, Ellis Selective glycosidase regimen for immune programming and treatment of cancer
CN111601606A (zh) * 2017-11-29 2020-08-28 菲格内有限责任公司 用于活化的成纤维细胞与免疫细胞的相互作用及其用途
US12485174B2 (en) 2019-06-27 2025-12-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-activated macrophages, compositions, and uses thereof
RU2717218C1 (ru) * 2019-08-07 2020-03-18 Зайцева Инга Николаевна Способ торможения роста подкожного трансплантата экспериментальной глиобластомы человека u-87, перевитого иммунодефицитным мышам nu/j
CN114854579A (zh) * 2022-04-13 2022-08-05 武汉大学 可用于临床的外周血特定亚群细胞外囊泡分离平台

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410269B1 (en) * 1995-06-07 2002-06-25 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US20050103712A1 (en) * 2003-11-13 2005-05-19 Voyce Brian D. Methods and devices for treating severe peripheral bacterial infections

Also Published As

Publication number Publication date
TW201113372A (en) 2011-04-16
EP2467154A2 (en) 2012-06-27
CN102596223A (zh) 2012-07-18
EP2467154A4 (en) 2013-03-27
WO2011028485A3 (en) 2011-07-14
CA2771900A1 (en) 2011-03-10
AU2010289901A1 (en) 2012-03-15
US20110123591A1 (en) 2011-05-26
WO2011028485A2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
IN2012DN02200A (enExample)
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2014135987A3 (en) Frequency optimization in ultrasound treatment
EP4585168A3 (en) A device for treatment of aneurysm
WO2011127211A3 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
CL2010001021A1 (es) Un metodo para operar un cabezal e terapia, de un sistema ultrasonico, para apoyar un tratamiento para contornear sitios corporales, y sistema ultrasonico para terapia cosmeticas.
WO2010047923A3 (en) Methods and systems for treating breast cancer using external beam radiation
PH12013500187A1 (en) Sirna targeting vegfa and methods for treatment in vivo
MX2015001716A (es) Niclosamida para el tratamiento de tumores solidos.
MX2011010511A (es) Regimen de tratamiento que utiliza neratinib para cancer de mama.
SI2124640T1 (sl) Glukoza izomeraza za uporabo v zdravljenju fruktozne intolerance
WO2010141143A3 (en) Engineered avirulent bacteria strains and use in medical treatments
WO2013120795A3 (en) Brachytherapy system & in vivo dose detector therefor
WO2008095164A3 (en) Biofeedback
CN201939733U (zh) 病原菌消杀器
CN202027947U (zh) 病原菌消杀器
WO2011098060A3 (de) Therapieoptimierung bei krebspatienten durch austesten von therapiekombinationen mittels in vitro testungen
RU2010136626A (ru) Способ усиления действия ультразвука при лечении гипертермией опухолевых тканей путем использования нанокластеров кремния
UA54725U (ru) Способ определения переносимости лекарственных средств при проведении первой фазы клинических исследований и исследовании биоэквивалентности
Островський Changes in the cells and tissues of living organisms under the influence of shock-wave therapy (literature review)
UA49735U (ru) Способ лечения больных гиперактивным мочевым пузырем с гиперкинетическим детрузором
UA61552U (ru) Способ лечения замедленной консолидации переломов и ложных суставов костей
TR200804036U (tr) Arter tespit ateli.
UA79016U (ru) Способ выбора показаний к оперативному лечению больных хроническим плевритом, совмещенным с легочными формами туберкулеза